Physician profile
David S Mohan
NPI 1578876785
$9,224.87
in general payments reported to CMS, 2019-2025
34 companies · $988 in 2025
The $988 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $1,004 · 2021: $2,232 · 2022: $1,837 · 2023: $1,131 · 2024: $1,148 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,267.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,792.99 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,076.40 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Sanofi-Aventis U.S. LLC | $1,042.04 | 2019-2023 | |
| Abbvie INC. | $663.90 | 2020-2025 | |
| Amgen INC. | $660.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.44 | 2019-2025 | Jardiance, Stiolto Respimat, Ofev |
| Glaxosmithkline, LLC. | $567.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $532.02 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $358.12 | 2019-2025 | |
| Amarin Pharma, INC. | $270.34 | 2019-2022 | |
| Exact Sciences Corporation | $198.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $180.23 | 2020-2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.95 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $154.21 | 2020-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $152.41 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $149.35 | 2025 | Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $74.57 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $59.32 | 2022-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $58.90 | 2021 | |
| Harmony Biosciences LLC | $57.23 | 2020-2022 | |
| Eisai INC. | $56.08 | 2021-2022 | |
| Corcept Therapeutics | $44.81 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $43.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.85 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $33.72 | 2022 | |
| Esperion Therapeutics, INC. | $32.98 | 2020-2025 | Nexletol |
| Allergan, INC. | $32.35 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $24.60 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.15 | 2021 | |
| Medtronic, INC. | $23.99 | 2025 | Inceptiv |
| Axsome Therapeutics, INC. | $18.52 | 2023 | Auvelity |
| Shire North American Group INC | $16.91 | 2019 | |
| Shield Therapeutics INC | $16.65 | 2024 | |
| Amneal Pharmaceuticals LLC | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.